Compliance to Multimodality Treatment for Oesophageal Cancer at a High Incidence Region of India
Authors:
- 21 July 2025
- journal article
- research article
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (5) , 970-978
Abstract
Oesophageal cancer (EC) is extremely aggressive in nature. Despite intensive multimodality treatment, survival is poor at the expense of high treatment–related morbidity. Meghalaya has the highest incidence of EC in India. Outcome of treatment for EC is dismal, and the compliance to the treatment is very low. This study strives to look for the compliance of patients to multimodality treatment at a tertiary hospital in Northeast India. This is an analysis of a prospectively maintained database (Ethics Committee approved) of all patients diagnosed with EC and advised management by the Multidisciplinary Team (MDT) at a tertiary health care centre at North East India between 31st January, 2023 and 31st December, 2024. The socio demographic, clinical, and treatment related details were recorded. The compliance to the treatment plan was assessed, with changes in the final treatment noted. Descriptive and analytical statistics were used. A total of 106 patients with EC were planned for curative (69.8%) and palliative (30.2%) treatment. The commonest ethnic background was Khasi-Jaintia tribe (88.6%%). Only 20.0% (12) of the patients who were advised neoadjuvant chemotherapy-surgery (NACT-Sx) or neoadjuvant chemoradiation-surgery (NACTRT-Sx) were able to complete the planned treatment. It was seen that 41(55.4%) patients receiving curative management were noncompliant. Patients belonging to urban region has higher odds of adherence to NACT-Sx [OR (95% CI): 1.400 (0.342–5.734)], NACTRT-Sx [OR (95% CI): 1.200 (0.304–4.743)], chemoradiation [OR (95% CI): 1.112 (0.983–1.842)], and palliative therapy [OR (95% CI): 1.015 (0.971–1.984)] than rural region. Compliance to multimodality treatment of EC at the study centre is poor. Further studies are recommended to find out the reason of low compliance to multimodality treatment.Keywords
This publication has 21 references indexed in Scilit:
- Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in TibetAsian Journal of Surgery, 2024
- Real-World Experience of Patient’s Compliance and Clinical Outcomes for Trimodality Treatment for Esophageal Cancer: a Study from a Cancer Center in North-East IndiaIndian Journal of Surgical Oncology, 2024
- Minimally Invasive Esophagectomy the Standard of Care: Experience from a Tertiary Care Cancer Center from IndiaIndian Journal of Surgical Oncology, 2021
- Indigenous and tribal peoples' health (The Lancet–Lowitja Institute Global Collaboration): a population studyThe Lancet, 2016
- Epidemiology, Diagnosis, and Management of Esophageal AdenocarcinomaGastroenterology, 2015
- Chemoradiation in oesophageal cancerBest Practice & Research Clinical Gastroenterology, 2015
- Multimodale Therapie des ÖsophaguskarzinomsDMW - Deutsche Medizinische Wochenschrift, 2014
- Role of Chemoradiotherapy in Oesophageal Cancer — Adjuvant and Neoadjuvant TherapyClinical Oncology, 2014
- Oesophageal carcinomaThe Lancet, 2013
- The Impact of Multimodality Therapy of Distal Esophageal and Gastroesophageal Junction Adenocarcinomas on Treatment-Related Toxicity and ComplicationsSeminars in Radiation Oncology, 2013